Clinical trial · Observational
Translation and Validation of MPCOSQ in Urdu Language
Translation and Validation of Modified Polycystic Ovary Syndrome Questionnaire in Urdu Language
NCT05010551CI-TRIAL-00058113completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To translate and validate modifies polycystic ovary syndrome quality of life (MPCOQ) questionnaire into Urdu. To evaluate the reliability, validity and of Urdu version of modified polycystic ovary syndrome quality of life questionnaire (MPCOQ).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PCOS- Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Modified polycystic ovary syndrome quality of life questionnaire
- timeFrame
- 6 months
- description
- The tool is to measure health related quality of life of females suffering from PCOS. it contains 30 items with 6 main areas related to hirsutism , acne, weight, infertility, emotional disturbance, menstrual difficulties to define different symptoms of PCOS. then quality of life will be measured of respective patients. The total is 210 with higher score indicating a better quality of life.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * • Age 18 - 30 * Married * Female patients diagnosed with PCOS, having 2 of the following Rotterdam diagnostic criteria: I. Polycystic ovaries visualized on ultrasound scan (presence of 12 follicles or more in one or both ovaries and/or increased ovarian volume \>10ml II. Clinical signs of hyperandrogenism (the hirsutism score based on the Ferriman-Gallwey score \>7 or obvious acne) III. Having an interval between menstrual periods \>35 days and/or amenorrhea as the absence of vaginal bleeding for at least 6 months, i.e. 199 days Patients who are willing to participate Exclusion Criteria: * • Non-adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia * Female undergoing Hormone Replacement Therapy * Female with malignancies * Any recent fractures, surgeries * Patient with nephrological and neurological conditions * Dementia or cognitive impairments
References
Publications (0)
Data not yet available
No reference posted for this study.